Benoit Cyr

Benoît Cyr serves as the Executive Chairman of Feldan since 2012, as a member of the board at Kalgen Pharmaceutical since 2017, and as an angel investor at Anges Québec since 2012.

Mr. Cyr was the President and Co-Founder of Biogenie Corporation and Biopharmacopae Design International. Biogenie, a company specializing in site remediation and organic waste management was acquired by Englobe in 2006, while Biopharmacopae was involved in the discovery and development of new active ingredients derived from plant extracts. Mr. Cyr’s work with Biopharmacopae led to the discovery and development of MMPs and cathepsin inhibitors for the treatment of cancer. He currently holds patents related to the treatment of contaminated soils and active therapeutic ingredients derived from plant extracts.

Through the years, Mr. Cyr invested in more than twenty start-ups specialized in biotechnology, drug development, medical devices (Cadence, Imagia, Incentia, Kalgene, Laurent Pharmaceuticals, Inversago), and additional industries. He also served on many boards of directors across those sectors.

Mr. Cyr obtained his bachelor’s and master’s degrees in agricultural and food engineering from Laval University in Quebec City.